La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MediciNova a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MediciNova..

MediciNova (NASDAQ:MNOV) Azioni, Catena delle Opzioni

MEDICINOVA INC

MediciNova

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.

MediciNova Inc

Analyst Ratings

Press Releases

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Health Care

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

News

Legal

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

Financing

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

MNOV

ABVC BioPharma

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

BeyondSpring

Cue Biopharma

CEL-SCI

Fortress Biotech

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

InflaRx

Immix Biopharma

MiNK Therapeutics

INmune Bio

Opus Genetics

Invivyd

Kala Bio

Metagenomi

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

OS Therapies

Ovid Therapeutics

Repare Therapeutics

D. Boral Capital

B. Riley Securities

Comments

MediciNova

MediciNova (MNOV) Opzioni

MediciNova (NASDAQ:MNOV) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO